The "Enterprise Tech Ecosystem Series: Boehringer Ingelheim 2025" company profile has been added to ResearchAndMarkets.com's offering. Boehringer Ingelheim International: Leading the Way in ...

Ingelheim, Germany and Amsterdam, the Netherlands, 23 April 2025 – Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches ...

Company prepares new product launches starting in 2025.

Pharmaceutical Technology is the independent source for information, insight, and analysis on bio/pharmaceutical formulation, development, and manufacturing.

Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer ...

German family-owned pharma major Boehringer Ingelheim and Dutch precision oncology company Tessellate Bio have entered into a ...

The survey confirms differences in perspectives: 65% of animal owners think veterinarians have a good work-life balance 1 while 48% of veterinarians say animal owners underappreciate the way they ...

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Boehringer Ingelheim has taken an option on a family ... that spans both pharmacological and digital therapeutic (DTx) products. Leading the charge for new drug therapies is iclepertin (also ...

Boehringer Ingelheim says it is planning to invest ... in its R&D last year as it pursues a goal of bringing 15 new products to market by 2025, the highest spend in its 137-year history and ...

With a market cap of $775.6 billion, Eli Lilly and Company (LLY) is a global biopharmaceutical leader with leading products ...